Referências

ALBERTS, B. et al. Biologia Molecular da Célula 3. ed. Porto Alegre: Artes Médicas, 1997.

AMBUDKAR, S.V. et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annual Review of Pharmacology and Toxicology, v.39, p.361-398, 1999.

AMEER, B. & WEINTRAUB, R.A. Drug interactions with grapefruit juice. Clinical Pharmacokinetics, v. 33, n. 2, p. 103-121, Aug. 1997.

ANDERSSON, T. et al. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clinical Pharmacology and Therapeutics, v. 47, n. 1, p. 79-85, Jan. 1990.

BACK, D.J. et al. The effect of rifampicin on norethisterone pharmacokinetics. European Journal of Clinical Pharmacology, v. 15, n. 3, p. 193-197, Apr. 1979.

BENET, L.Z.; KROETZ, D.L.; SHEINER, L.B. Farmacocinética: A dinâmica da absorção, distribuição e eliminação dos fármacos. In: HARDMAN, J.G.; LIMBIRD, L. E. (eds.) Goodman e Gilman: As Bases Farmacológicas da Terapêutica 9. ed. Rio de Janeiro: McGraw-Hill, 1996.

BERNDT, W.O. & STITZEL, R.E. Excreção de Drogas. In: CRAID, C.R. & STITZEL, R.E. Farmacologia Moderna 4. ed. Rio de Janeiro: Guanabara Koogan, 1996. p. 45-50.

BERNER, W. & KINNE, R. Transport of p-aminohippuric acid by plasma membrane vesicles isolated from rat kidney cortex. Pflugers Archiv. European Journal of Physiology, v. 361, n. 3, p. 269-277, Feb. 1976.

BERTZ, R.J. & GRANNEMAN, G.R. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clinical Pharmacokinetics, v. 32, n. 3, p. 210-258, Mar. 1997.

BONATE, P.L.; REITH, K.; WEIR, S. Drug interactions at the renal level. Implications for drug development. Clinical Pharmacokinetics, v. 34, n. 5, p. 375-404, May 1998.

BONDON, A. et al. Oxidation of cycloalkylamines by cytochrome P-450. Mechanism-based inactivation, adduct formation, ring expansion, and nitrone formation. Journal of Biological Chemistry, v. 264, n. 4, p. 1988-1997, Feb. 1989.

BRODIE, B. B. Physiochemical factors in drug absorption. In: BINNS, T.B. (ed.) Absorption And Distribution Of Drugs. Baltimore: The Williams E Wilkins Co., 1964. p. 16-48.

CARVER, P.L. et al. Meal composition effects on the oral bioavailability of indinavir in HIV-infected patients. Pharmaceutical Research, v. 16, n. 5, p. 718-724, May 1999.

CAVET, M.E.; WEST, M.; SIMMONS, N.L. Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells. British Journal of Pharmacology, v. 118, n. 6, p. 1389-1396, July 1996.

COSTA, T.D. & STRECK, E.L. Isoformas do citocromo P450 e outros fatores que alteram a biotransformação de fármacos Infarma, v. 11, n. 11/12, p. 36-41, nov./dez. 1999.

D’ARCY, P.F. & MCELNAY, J.C. Drug interactions involving the displacement of drugs from plasma protein and tissue binding sites Pharmacology and Therapeutics, v. 17, n. 2, p. 211-220, 1982.

DANAN, G.; DESCATOIRE, V.; PESSAYRE, D. Self-induction by erythromycin of its own transformation into a metabolite forming an inactive complex with reduced cytochrome P-450. Journal of Pharmacology and Experimental Therapeutics, v. 218, n. 2, p. 509-514, Aug. 1981.

DANIELS, N.J.; DOVER, J.S.; SCHACHTER, R.K. Interaction between cyclosporin and rifampicin. Lancet, v. 2, n. 8403, p. 639, Sep. 1984.

DE MATTEIS, F. et al. Inactivation of cytochrome P-450 and production of N-alkylated porphyrins caused in isolated hepatocytes by substituted dihydropyridines. Structural requirements for loss of haem and alkylation of the pyrrole nitrogen atom. Febs Letters , v. 145, n. 1, p. 87-92, Aug. 1982.

DECKER, C.J. et al. Oxidative metabolism of spironolactone: evidence for the involvement of electrophilic thiosteroid species in drug-mediated destruction of rat hepatic cytochrome P450. Biochemistry, v. 28, n. 12, p. 5128-5136, June 1989.

ELIASSON, E.; JOHANSSON, I.; INGELMAN-SUNDBERG, M. Substrate-, hormone-, and cAMP-regulated cytochrome P450 degradation. Proceedings of The National Academy of Sciences of USA, v. 87, n. 8, p. 3225-3229, Apr. 1990.

FLEISHER, D. et al. Drug, Meal and Formulation Interactions Influencing Drug Absorption After Oral Administration. Clinical Pharmacokinetics, v. 36, n. 3, p. 169-254, Mar. 1999.

FONSECA, A.L. Interações Medicamentosas Rio De janeiro: Editora De Publicações Científicas, 1991.

GIBALDI, M. & LEVY, G. Pharmacokinetics in clinical practice. I. Concepts. Jama : The Journal of The American Medical Association, v. 235, n. 17, p. 1864-1867, Apr. 1976.

GONZALEZ, F.J. The molecular biology of cytochrome P450s. Pharmacological Reviews, v. 40, n. 4, p.243-288, Dec. 1988.

GREENBLATT, D.J. & KOCH-WESWER, J. Clinical pharmacokinetics. New England Journal of Medicine, v. 293, n. 19, p. 964-970, Nov. 1975.

GREIFF, J. M. & ROWBOTHAM, D. Pharmacokinetic drug interactions with gastrointestinal motility modifying agents. Clinical Pharmacokinetics, v. 27, n. 6, p. 447-461, Dec. 1994.

GUENGERICH, F.P. Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450. Molecular Pharmacology, v. 33, n. 5, p. 500-508, May 1988.

HALPERT, J.R. Covalent modification of lysine during the suicide inactivation of rat liver cytochrome P-450 by chloramphenicol. Biochemical Pharmacology, v. 30, n. 8, p. 875-881, Apr. 1981.

HALPERT, J.R. Structural basis of selective cytochrome P450 inhibition. Annual Review of Pharmacology and Toxicology, v. 35, p. 29-53, 1995.

HALPERT, J.R. et al. Isozyme selectivity of the inhibition of rat liver cytochromes P-450 by chloramphenicol in vivo. Molecular Pharmacology, v. 28, n. 3, p. 290-296, Sep. 1985.

HAMAR, C. & LEVY, G. Serum protein binding of drugs and bilirubin in newborn infants and their mothers. Clinical Pharmacology and Therapeutics, v. 28, n. 1, p. 58-63, July 1980.

HANG, P.H.; DALE, M.M.; RITTER, J.M. Farmacologia 3. ed. Rio de Janeiro: Guanabara Koogan, 1997.

HAWK, C.T. & DANTZLER, W.H. Tetraethylammonium transport by isolated perfused snake renal tubules. American Journal of Physiology, v. 246, n. 4 Pt 2, p. F476-F487, Apr. 1984.

HEIMARK LD et al. The mechanism of the warfarin-rifampin drug interaction in humans. Clinical Pharmacology and Therapeutics, v. 42, n. 4, p. 388-394, Oct. 1987.

HONIG, P.K. et al. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. Jama : The Journal of The American Medical Association, v. 269, n. 12, p. 1513-1518, Mar. 1993.

HUANG, J.D. & OIE, S. Hepatic elimination of drugs with concentration-dependent serum binding. Journal of Pharmacokinetics and Biopharmaceutics, v. 12, n. 1, p. 67-81, Feb. 1984.

HUUPPONEN, R.; SEPPALA, P.; LISALO, E. Effect of guar gum, a fibre preparation, on digoxina e penicillin absorption in man. European Journal of Clinical Pharmacology, v. 26, n. 2, p. 279-291, 1984.

INGELMAN-SUNDBERG, M.; OSCARSON, M.; MCLELLAN, R.A. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends in Pharmacological Sciences, v. 20, n. 8, p. 342-349, Aug. 1999.

INOUE, M. et al. Mechanism of furosemide resistance in analbuminemic rats and hypoalbuminemic patients. Kidney International, v. 32, n. 2, p. 198-203, Aug. 1987.

JONEN, H.G. et al. Influence of pyridine and some pyridine derivatives on spectral properties of reduced microsomes and on microsomal drug metabolizing activity. Biochemical Pharmacology, v. 23, n. 8, p. 1319-1329, Apr. 1974.

KEMPF, D.J. et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrobial Agents and Chemotherapy, v. 41, n. 3, p. 654-660, Mar. 1997.

KEOGH, A. et al. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. New England Journal of Medicine, v. 333, n. 10, p. 628-633, Sep. 1995.

KINSELLA, J.L. et al. Transport of organic ions in renal cortical luminal and antiluminal membrane vesicles. Journal of Pharmacology and Experimental Therapeutics, v. 209, n. 3, p. 443-450, June 1979.

KOBER, A.; OLSSON, Y.; SJOHOLM, I. Binding of drugs to human serum albumin. XIV. The theoretical basis for the interaction between phenytoin and valproate. Molecular Pharmacology, v. 18, n. 2, p. 237-242, Sep. 1980.

KOCH-WESER, J. & SELLERS, E.M. Drug therapy. Binding of drugs to serum albumin (second of two parts). New England Journal of Medicine, v. 294, n. 10, p. 526-531, Mar. 1976.

LEAHEY, E.B. et al Interaction between quinidine and digoxin. Jama : The Journal of The American Medical Association, v. 240, n. 6, p. 533-534, Aug. 1978.

LEHNINGER, A.L. Princípios de Bioquímica São Paulo: Sarvier, 1986.

LESCA, P. et al. A class of strong inhibitors of microsomal monooxygenases: the ellipticines. Chemico-Biological interactions, v. 24, n. 2, p. 189-197, Feb. 1979.

LEVY, G. Effect of plasma protein binding on renal clearance of drugs. Journal of Pharmaceutical Sciences, v. 69, n. 4, p. 482-483, Apr. 1980.

LEVY, G. & YACOBI, A. Letter: Effect of plasma protein binding on elimination of warfarin. Journal of Pharmaceutical Sciences, v. 63, n. 5, p. 805-806, May 1974.

LIN, J.H. & LU, A.Y. Inhibition and induction of cytochrome P450 and the clinical implications. Clinical Pharmacokinetics, v. 35, n. 5, p. 361-390, Nov. 1994.

LINDBERG, M.C.; CUNNINGHAM, A.; LINDBERG, N.H. 7 Acute phenobarbital intoxication. Southern Medical Journal, v. 85, n. 8, p. 803-807, Aug. 1992.

LOMAESTRO, B.M. & BAILE, G.R. Absorption interactions with fluoroquinolones: 1995 update. Drug Safety, v. 12, n. 5, p. 314-333, May 1995.

LOPEZ GARCIA, M.P. et al. Human-liver cytochromes P-450 expressed in yeast as tools for reactive-metabolite formation studies. Oxidative activation of tienilic acid by cytochromes P-450 2C9 and 2C10. European Journal of Biochemistry, v. 213, n. 1, p. 223-232, Apr. 1993.

MCELNAY, J.C. & D’ARCY, P.F. Protein binding displacement interactions and their clinical importance. Drugs, v. 25, n. 5, p. 495-513, May 1983.

MELLO, A.C. Biotransformação das drogas. In: SILVA, P. Farmacologia 5. ed. Rio de Janeiro: Guanabara Koogan, 1998. p. 51-57.

MUAKKASSAH, S.F.; BIDLACK, W.R.; YANG, W.C. Mechanism of the inhibitory action of isoniazid on microsomal drug metabolism. Biochemical Pharmacology, v. 30, n. 12, p. 1651-1658, June 1981.

MURRAY, M. & FARREL, G.C. Mechanistic aspects of the inhibition of microssomal drug oxidation by primaquine. Biochemical Pharmacology, v. 35, n. 13, p. 2149-2155, July 1986.

NELSON, D.R. et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics, v. 6, n. 1, p. 1-42, Feb. 1996.

OGA, S.; BASILE, A.C.; Medicamentos e suas Interações São Paulo: Atheneu, 1994.

PARK, B.K. et al. Relevance of inductuion of human drug-metabolizing enzymes: pharmacological and toxicological implications. British Journal of Clinical Pharmacology, v. 41, n. 6, p. 477-491, June 1996.

PESSAYRE, D. et al. Self-induction by oleandomycin of its own transformation into a metabolite forming an inactive complex with reduced cytochrome P-450. Comparison with troleandomycin. Journal of Pharmacology and Experimental Therapeutics, v. 221, n. 1, p. 215-221, Apr. 1982a.

PESSAYRE, D. et al. Formation of an inactive cytochrome P-450 Fe(II)-metabolite complex after administration of troleandomycin in humans. Biochemical Pharmacology, v. 31, n. 9, p. 1699-1704, May 1982b.

PIKE, S.F. et al. Induction of cytocrome P-450 by phenobarbital is mediated at the level of transcription. Biochemical Pharmacology, v. 34, n. 14, p. 2489-2494, July 1985.

PINCKARD, R.N.; HAWKINS, D.; FARR, R.S. The influence of acetylsalicyclic acid on the binding of acetrizoate to human albumin. Annals of The New York Academy of Sciences, v. 226, p. 341-354, Nov. 1973.

POLAND, A.; GLOVER, E.; KENDE, A.S. Stereospecific, high affinity binding of 2,3,7,8-tetrachlorodibenzo-p-dioxin by hepatic cytosol. Evidence that the binding species is receptor for induction of aryl hydrocarbon hydroxylase. Journal of Biological Chemistry, v. 251, n. 16, p. 4936-4946, Aug. 1976.

PRITCHARD, J.B. Intracellular alpha-ketoglutarate controls the efficacy of renal organic anion transport. Journal of Pharmacology and Experimental Therapeutics, v. 274, n. 3, p. 1278-1284, Sep. 1995.

PRITCHARD, J.B. & MILLER, D.S. Mechanisms mediating renal secretion of organic anions and cations. Physiological Reviews, v. 73, n. 4, p. 765-796, Oct. 1993.

PRITCHARD, J.B. & MILLER, D.S. Renal secretion of organic anions and cations. Kidney International, v. 49, n. 6, p. 1649-1654, June 1996.

PRITCHARD, J.B. et al. ATP-dependent transport of tetraethylammonium by endosomes isolated from rat renal cortex. American Journal of Physiology, v. 266, n. 6 Pt 2, p. F966-F976, June 1994.

REIDY, G.F.; MEHTA, I.; MURRAY, M. Inhibition of oxidative drug metabolism by orphenadrine: in vitro and in vivo evidence for isozyme-specific complexation of cytochome P-450 and inhibition kinetics. Molecular Pharmacology, v. 35, n. 5, p. 736-743, May 1989.

RIVA, R. et al. Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations. Clinical Pharmacokinetics, v. 31, n. 6, p. 470-493, Dec. 1996.

ROBERTS, E.S. et al. Mechanism-based inactivation of cytochrome P450 2B1 by 2-ethynylnaphthalene: identification of an active-site peptide. Chemical Research in Toxicology, v. 6, n. 4, p. 470-479, July/Aug. 1993.

ROCH-RAMEL, F. Renal transport of organic anions. Current Opinion in Nephrology and Hypertension, v. 7, n. 5, p. 517-524, Sep. 1998.

ROWLAND, M. Plasma protein binding and therapeutic drug monitoring. Therapeutic Drug Monitoring, v. 2, n. 1, p. 29-37, 1980.

SCHALI, C. et al. Secretion of tetraethylammonium by proximal tubules of rabbit kidneys. American Journal of Physiology, v. 245, n. 2, p. F238-F246, Aug. 1983.

SELLERS, E.M. Interações entre drogas. In: KALANT, H. & ROSCHLAU, W.H.E. Princípios de Farmacologia Médica 5. ed. Rio de Janeiro: Guanabara Koogan, 1991. p. 89-96.

SELLERS, E.M. & KOCH-WESER, J. Displacement of warfarin from human albumin by diazoxide and ethacrynic,mefenamic, and nalidixic acids. Clinical Pharmacology and Therapeutics, v. 11, n. 4, p. 524-529, July/Aug. 1970.

SHAW, G.C. & FULCO, A.J. Inhibition by barbiturates of the binding of Bm3R1 repressor to its operator site on the barbiturate-inducible cytochrome P450BM-3 gene of Bacillus megaterium. Journal of Biological Chemistry, v. 268, n. 4, p. 2997-3004, Feb. 1993.

SHAW, P.N. et al. Antipyrine metabolite kinetics in healthy human volunteers during multiple dosing of phenytoin and carbamazepine. British Journal of Clinical Pharmacology, v. 20, n. 6, p. 611-618, Dec. 1985.

SHIMADA, H.; MOEWES, B.; BURCKHARDT, G. Indirect coupling to Na+ of p-aminohippuric acid uptake into rat renal basolateral membrane vesicles. American Journal of Physiology, v. 253, n. 5 Pt 2, p. F795-F801, Nov. 1987.

SILVA, P. Farmacologia 5. ed. Rio de Janeiro: Guanabara Koogan, 1998. p. 12-19.

SMITH, P.M.; PRITCHARD, J.B.; MILLER DS Membrane potential drives organic cation transport into teleost renal proximal tubules. American Journal of Physiology, v. 255, n. 3 Pt 2, p. R492-R499, Sep. 1988.

SOMOGYI, A. Renal transport of drugs: Specificity and Molecular Mechanisms. Clinical and Experimental Pharmacology and Phisiology, v. 23, n. 10/11, p. 986-989, Oct./Nov. 1996.

SOMOGYI, A.; MCLEAN, A.; HEINZOW, B. Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs. European Journal of Clinical Pharmacology, v. 25, n. 3, p. 339-345, 1983.

STEEL, K. et al. Iatrogenic illness on a general service at a university hospital. New England Journal of Medicine, v. 304, n. 11, p. 638-642, Mar. 1981.

TANAKA, E. Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes. Journal of Clinical Pharmacy & Therapeutics, v. 23, n. 6, p. 403-416, Dec. 1998

TANIGAWARA, Y. et al. Transport of digoxin by human p-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). Journal of Pharmacology and Experimental Therapeutics, v. 263, n. 2, p. 840-845, Nov. 1992.

THOMAS, P.E. et al Induction of two immunochemically related rat liver cytochrome P-450 isozymes, cytochromes P-450c and P-450d, by structurally diverse xenobiotics. Journal of Biological Chemistry, v. 258, n. 7, p. 4590-4598, Apr. 1983.

TURGEON, J. et al. Genetically determined steady-state interaction between encainide and quinidine in patients with arrhythmias. Journal of Pharmacology and Experimental Therapeutics, v. 255, n. 2, p. 642-649, Nov. 1990.

ULLRICH, K.J. & RUMRICH, G. Contraluminal transport systems in the proximal renal tubule involved in secretion of organic anions. American Journal of Physiology, v. 254, n. 4 Pt 2, p. F453-F462, Apr. 1988.

VLASSES, P.H. et al. Trimethoprim inhibition of the renal clearance of procainamide and N-acetylprocainamide. Archives of internal Medicine, v. 149, n. 6, p. 1350-1353, June 1989.

WHITLOCK, J.P. Jr Mechanistic aspects of dioxin action. Chemical Research in Toxicology, v. 6, n. 6, p. 754-763, Nov./Dec. 1993.

WOODLAND, C. et al. The digoxin-propafenone interaction: Characterization of a mechanism usind renal tubular cell monolayers The Journal of Pharmacology and Experimental Therapeutics, v. 283, n. 1, p. 39-45, Oct. 1997.

ZHOU, H.H. et al. Induction of polymorphic 4-hydroxylation of S-mephenytoin by rifampicin. British Journal of Clinical Pharmacology, v. 30, n. 3, p. 471-475, Sep. 1990.

ZHOU, S.Y. et al. Intestinal metabolism and transport od 5-aminosalicylate Drug Metabolism and Disposition, v. 27, n. 4, p. 479-485, Apr. 1999.